Although injectable cabotegravir/rilpivirine is still yet to be approved by the FDA, evidence keeps mounting on the effectiveness of the shot for HIV treatment.
Researchers are happy but cautious, because this isn’t a strategy for most people with HIV.
Long-Acting Injectable HIV Meds Just as Good as Daily Pill for Newly Diagnosed and Those Already Undetectable
Questions still remain as to when FDA will approve, and how it will be implemented.
COVID-19 will impact both the program content and attendees this year, but there are still important HIV science presentations.
While the vaginal ring is still currently under FDA review, the new study will show whether it is safe and acceptable for people who are pregnant.
HVTN 702 is but one of many vaccine trials underway, researchers note.
Using data from the ADVANCE trial, this researcher suggests people with HIV with low-level viremia may still get to undetectable.
This may be a temporary setback, but long-acting antiretroviral therapy is still on the way, experts say.
The likely launch of injectable cabotegravir/rilpivirine in early 2020 will be interesting, writes David Wohl, M.D. One big question: How smoothly will the rollout go?
This is clearly an antiretroviral not built for daily administration. But then what is it destined for?